PNP with Waldenström's macroglobulinaemia

Clinical and Experimental Dermatology

Volumn 30, Issue 1, 2005, Pages 27-29

  Perera, G K ^a   Devereux, S ^a   Mufti, G ^a   Salisbury, J ^a   Creamer, D ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CLOBETASOL PROPIONATE; EMOLLIENT AGENT; EPITOPE; EYE DROPS; FLUDARABINE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE SODIUM PHOSPHATE; RITUXIMAB;

AGED; ARTICLE; AUTOIMMUNITY; CASE REPORT; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; HUMAN TISSUE; LICHENOID; MALE; PARANEOPLASTIC SYNDROME; PEMPHIGUS; PLASMAPHERESIS; PRIORITY JOURNAL; RARE DISEASE; WALDENSTROEM MACROGLOBULINEMIA;

AGED; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; FATAL OUTCOME; HUMANS; MALE; PARANEOPLASTIC SYNDROMES; PEMPHIGUS; SKIN NEOPLASMS; VIDARABINE; WALDENSTROM MACROGLOBULINEMIA;

EID: 13244258385     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2004.01599.x     Document Type: Article

References (16)

1. Anhalt GJ, Kim SC, Stanley JR et al. Paraneoplastic pemphigus: an autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990; 323: 1729-35.
2. Mimouni D, Anhalt GJ, Lazarova Z et al. Paraneoplastic pemphigus in children and adolescents. Br J Dermatol 2002; 147: 725-32.
3. Anhalt G. Paraneoplastic pemphigus. Adv Dermatol 1997; 12: 77-96.
4. Hashimoto T, Amagi M, Watanabe K et al. Characterisation of paraneoplastic pemphigus autoantigens by immunoblot analysis. J Invest Dermatol 1995; 104: 829-34.
5. Joly P, Richard C, Gilbert D et al. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol 2000; 43: 619-26.
6. Becker LR, Bastian BC, Wesselmann U et al. Paraneoplastic pemphigus treated with dexamethasone/cyclophosphamide pulse therapy. Eur J Dermatol 1998; 8: 551-3.
7. Anon. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 19-1992. A 56-year-old man with Waldenstrom's macroglobulinaemia and cutaneous and oral vesicles. N Engl J Med 1992; 326: 1276-84.
8. Anhalt GJ. Paraneoplstic pemphigus, the role of tumours and drugs. Br J Dermatol 2001; 144: 1102-4.
9. Braess J, Reich K, Wilbert S et al. Mucocutaneous autoimmune syndrome following fludarabine therapy for non-Hodgkin's lymphoma of B-cell type (BNHL). Ann Haematol 1997; 75: 227-30.
10. Gooptu C, Littlewood TJ, Frith P et al. Paraneoplastic pemphigus: an association with fludarabine? Br J Dermatol 2001; 144: 1255-61.
11. Vanderglut CJ, Miller SD. Epitope spreading. Curr Opin Immunol 1996; 8: 831-6.
12. Bowen GM, Peters NT, Fivenson DP et al. Lichenoid dermatitis in paraneoplastic pemphigus: a pathogenic trigger of epitope spreading? Arch Dermatol 2000; 136: 652-6.
13. Horn TD, Anhalt GJ. Histologic features of paraneoplastic pemphigus. Arch Dermatol 1992; 128: 1091-5.
14. Nguyen VT, Ndoye A, Bassler KD et al. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome. Arch Dermatol 2001; 137: 193-207.
15. Borradori L, Lombardi T, Samson J et al. Anti-CD20 monoclonal antibody (Rituximab) for refractory erosive stomatitis secondary to CD20+ follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol 2001; 137: 269-72.
16. Williams JV, Marks JG Jr, Billingsley EM. Use of mycophenolate mofetil in the treatment of paraneoplastic pemphigus. Br J Dermatol 2000; 142: 506-8.